Adam Forrestine

Person

Mentions

Episodes

Claims

Adam Forrestine, mentioned 8 times across podcast episodes and expert conversations analyzed by Sonic.

What Adam Forrestine has said

A drug that Pfizer divested to Roivant was subsequently developed by Roivant into a multi-billion dollar asset.

mixed·Adam Forrestine

Vertex Pharmaceuticals announced positive Phase 2 results for its drug VX-548, showing significant pain reduction in patients with chronic nerve pain from diabetes.

bullish·Adam Forrestine

Vertex Pharmaceuticals is currently running Phase 3 studies for its pain drug VX-548 in acute pain settings, with data expected in early 2024.

bullish·Adam Forrestine

A drug that Pfizer divested to Roivant was subsequently developed by Roivant into a multi-billion dollar asset.

Expert perspectiveAdam ForrestineApr 20

Vertex Pharmaceuticals announced positive Phase 2 results for its drug VX-548, showing significant pain reduction in patients with chronic nerve pain from diabetes.

Expert perspectiveAdam ForrestineApr 20

Vertex Pharmaceuticals is currently running Phase 3 studies for its pain drug VX-548 in acute pain settings, with data expected in early 2024.

Expert perspectiveAdam ForrestineApr 20

The scientific foundation for both Vertex's cystic fibrosis drugs and its new pain drug originated from a company called Aurora, which Vertex acquired for approximately $500 million.

Expert perspectiveAdam ForrestineApr 20

Vertex Pharmaceuticals' cystic fibrosis drugs are expected to generate approximately $10 billion in annual revenue at their peak.

Expert perspectiveAdam ForrestineApr 20

Jason Coloma, CEO of Maize Therapeutics, expressed disappointment that Sanofi chose to walk away from their deal instead of fighting the FTC's challenge.

Expert perspectiveAdam ForrestineApr 20

Vertex Pharmaceuticals' market capitalization crossed the $100 billion threshold on December 13, 2023.

Expert perspectiveAdam ForrestineApr 20

Vertex Pharmaceuticals' pain drug, VX-548, is a non-opioid and does not have the addictive qualities of opioids.

Expert perspectiveAdam ForrestineApr 20

Create a free account to see Adam Forrestine's full intelligence report - every claim, the relationship network, and AI Q&A across all sources. No card needed.

Get started free

Back to Entities Entity Detail